1. Sawyers, C.L. The cancer biomarker problem. Nature452, 548-552 (2008).
2. Lemery, S., Keegan, P. & Pazdur, R. First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. N Engl J Med377, 1409-1412 (2017).
3. Zhang, P., et al. Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip. Nat Biomed Eng3, 438-451 (2019).
4. Jayaseelan, V.P. Emerging role of exosomes as promising diagnostic tool for cancer. Cancer Gene Ther27, 395-398 (2020).
5. Sheridan, C. Exosome cancer diagnostic reaches market. Nat Biotechnol34, 359-360 (2016).
6. Fu, W., et al. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nat Commun10, 4355 (2019).
7. Daassi, D., Mahoney, K.M. & Freeman, G.J. The importance of exosomal PDL1 in tumour immune evasion. Nat Rev Immunol20, 209-215 (2020).
8. Yong, T., et al. Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy. Nat Commun10, 3838 (2019).
9. Thery, C., Zitvogel, L. & Amigorena, S. Exosomes: composition, biogenesis and function. Nat Rev Immunol2, 569-579 (2002).
10. Moller, A. & Lobb, R.J. The evolving translational potential of small extracellular vesicles in cancer. Nat Rev Cancer20, 697-709 (2020).
11. Willms, E., Cabanas, C., Mager, I., Wood, M.J.A. & Vader, P. Extracellular Vesicle Heterogeneity: Subpopulations, Isolation Techniques, and Diverse Functions in Cancer Progression. Front Immunol9, 738 (2018).
12. Furi, I., Momen-Heravi, F. & Szabo, G. Extracellular vesicle isolation: present and future. Ann Transl Med5, 263 (2017).
13. van Niel, G., D'Angelo, G. & Raposo, G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol19, 213-228 (2018).
14. Roy, S., et al. Navigating the Landscape of Tumor Extracellular Vesicle Heterogeneity. Int J Mol Sci20(2019).
15. Zabeo, D., et al. Exosomes purified from a single cell type have diverse morphology. J Extracell Vesicles6, 1329476 (2017).
16. Kalluri, R. & LeBleu, V.S. The biology, function, and biomedical applications of exosomes. Science367(2020).
17. Thery, C., et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles7, 1535750 (2018).
18. Witwer, K.W., et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles2(2013).
19. Coughlan, C., et al. Exosome Isolation by Ultracentrifugation and Precipitation and Techniques for Downstream Analyses. Curr Protoc Cell Biol88, e110 (2020).
20. Bobrie, A., Colombo, M., Krumeich, S., Raposo, G. & Thery, C. Diverse subpopulations of vesicles secreted by different intracellular mechanisms are present in exosome preparations obtained by differential ultracentrifugation. J Extracell Vesicles1(2012).
21. Yang, D., et al. Progress, opportunity, and perspective on exosome isolation - efforts for efficient exosome-based theranostics. Theranostics10, 3684-3707 (2020).
22. Taylor, D.D., Zacharias, W. & Gercel-Taylor, C. Exosome isolation for proteomic analyses and RNA profiling. Methods Mol Biol728, 235-246 (2011).
23. Marques-Garcia, F. & Isidoro-Garcia, M. Protocols for Exosome Isolation and RNA Profiling. Methods Mol Biol1434, 153-167 (2016).
24. Contreras-Naranjo, J.C., Wu, H.J. & Ugaz, V.M. Microfluidics for exosome isolation and analysis: enabling liquid biopsy for personalized medicine. Lab Chip17, 3558-3577 (2017).
25. He, M., Crow, J., Roth, M., Zeng, Y. & Godwin, A.K. Integrated immunoisolation and protein analysis of circulating exosomes using microfluidic technology. Lab Chip14, 3773-3780 (2014).
26. Cai, S., et al. Immuno-modified superparamagnetic nanoparticles via host-guest interactions for high-purity capture and mild release of exosomes. Nanoscale10, 14280-14289 (2018).
27. Clayton, A., et al. Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry. J Immunol Methods247, 163-174 (2001).
28. Sun, N., et al. Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring. Nat Commun11, 4489 (2020).
29. Dong, J., et al. Coupling Nanostructured Microchips with Covalent Chemistry Enables Purification of Sarcoma-Derived Extracellular Vesicles for Downstream Functional Studies. Adv Funct Mater30(2020).
30. Wilson, J.L., Jr., Antoniassi, M.P., Lopes, P.I. & Azevedo, H. Proteomic research and diagnosis in bladder cancer: state of the art review. Int Braz J Urol47, 503-514 (2021).
31. Lu, C.H., Yang, H.H., Zhu, C.L., Chen, X. & Chen, G.N. A graphene platform for sensing biomolecules. Angew Chem Int Ed Engl48, 4785-4787 (2009).
32. Grande Tovar, C.D., et al. Synthesis of Chitosan Beads Incorporating Graphene Oxide/Titanium Dioxide Nanoparticles for In Vivo Studies. Molecules25(2020).
33. Li, J., et al. Gold nanoparticle-glutathione-functionalized porous graphene oxide-based hydrophilic beads for the selective enrichment of N-linked glycopeptides. Mikrochim Acta187, 518 (2020).
34. Pham, X.H., et al. Graphene Oxide Conjugated Magnetic Beads for RNA Extraction. Chem Asian J12, 1883-1888 (2017).
35. Ouyang, A., et al. Highly Porous Core-Shell Structured Graphene-Chitosan Beads. ACS Appl Mater Interfaces7, 14439-14445 (2015).
36. Yi, E.S., Strong, C.R., Piao, Z., Perucho, M. & Weidner, N. Epithelioid gastrointestinal stromal tumor with PDGFRA activating mutation and immunoreactivity. Appl Immunohistochem Mol Morphol13, 157-161 (2005).
37. Eliyakin, N., Postaci, H., Baskin, Y. & Kozacioglu, Z. Small Cell Carcinoma of the Urinary Bladder: KIT and PDGFRA Gene Mutations. Rare Tumors7, 5982 (2015).
38. Hermanns, T., et al. A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade. Urol Oncol38, 603 e601-603 e607 (2020).
39. Ku, J.H., Godoy, G., Amiel, G.E. & Lerner, S.P. Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review. BJU Int110, 630-636 (2012).
40. Sabo, A.A., et al. Small Non-Coding RNA Profiling in Plasma Extracellular Vesicles of Bladder Cancer Patients by Next-Generation Sequencing: Expression Levels of miR-126-3p and piR-5936 Increase with Higher Histologic Grades. Cancers (Basel)12(2020).
41. Berrondo, C., et al. Expression of the Long Non-Coding RNA HOTAIR Correlates with Disease Progression in Bladder Cancer and Is Contained in Bladder Cancer Patient Urinary Exosomes. PLoS One11, e0147236 (2016).
42. Abbastabar, M., et al. Tumor-derived urinary exosomal long non-coding RNAs as diagnostic biomarkers for bladder cancer. EXCLI J19, 301-310 (2020).
43. Bell, M.D., et al. Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study. World J Urol34, 1405-1409 (2016).
44. Abramowicz, A. & Story, M.D. The Long and Short of It: The Emerging Roles of Non-Coding RNA in Small Extracellular Vesicles. Cancers (Basel)12(2020).
45. Zhao, W., Liu, Y., Zhang, C. & Duan, C. Multiple Roles of Exosomal Long Noncoding RNAs in Cancers. Biomed Res Int2019, 1460572 (2019).
46. Dragomir, M., Chen, B. & Calin, G.A. Exosomal lncRNAs as new players in cell-to-cell communication. Transl Cancer Res7, S243-S252 (2018).
47. Mussack, V., Wittmann, G. & Pfaffl, M.W. Comparing small urinary extracellular vesicle purification methods with a view to RNA sequencing-Enabling robust and non-invasive biomarker research. Biomol Detect Quantif17, 100089 (2019).
48. Cha, D.J., et al. KRAS-dependent sorting of miRNA to exosomes. Elife4, e07197 (2015).
49. Stark, M.S., et al. Characterization of the Melanoma miRNAome by Deep Sequencing. PLoS One5, e9685 (2010).
50. Huang, J., et al. miR-92b targets DAB2IP to promote EMT in bladder cancer migration and invasion. Oncol Rep36, 1693-1701 (2016).
51. Zhao, S., et al. Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer. J Hematol Oncol13, 156 (2020).
52. Beckham, C.J., et al. Bladder cancer exosomes contain EDIL-3/Del1 and facilitate cancer progression. J Urol192, 583-592 (2014).
53. Oeyen, E., et al. Bladder Cancer Diagnosis and Follow-Up: The Current Status and Possible Role of Extracellular Vesicles. Int J Mol Sci20(2019).
54. Li, Q., et al. IRAK4 mediates colitis-induced tumorigenesis and chemoresistance in colorectal cancer. JCI Insight4(2019).
55. Birkenkamp-Demtroder, K., et al. Keratin23 (KRT23) knockdown decreases proliferation and affects the DNA damage response of colon cancer cells. PLoS One8, e73593 (2013).
56. Fattahi Dolatabadi, N., et al. The interaction between MALAT1 target, miR-143-3p, and RALGAPA2 is affected by functional SNP rs3827693 in breast cancer. Hum Cell33, 1229-1239 (2020).
57. Goodison, S., Rosser, C.J. & Urquidi, V. Urinary proteomic profiling for diagnostic bladder cancer biomarkers. Expert Rev Proteomics6, 507-514 (2009).
58. Wiklander, O.P., et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J Extracell Vesicles4, 26316 (2015).
59. Harada, Y., et al. Generation of the heterogeneity of extracellular vesicles by membrane organization and sorting machineries. Biochim Biophys Acta Gen Subj1863, 681-691 (2019).
60. Naito, Y., et al. Cancer extracellular vesicles contribute to stromal heterogeneity by inducing chemokines in cancer-associated fibroblasts. Oncogene38, 5566-5579 (2019).
61. Colombo, M., et al. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. J Cell Sci126, 5553-5565 (2013).
62. Giebel, B. On the function and heterogeneity of extracellular vesicles. Ann Transl Med5, 150 (2017).
63. Paolini, L., et al. Fourier-transform Infrared (FT-IR) spectroscopy fingerprints subpopulations of extracellular vesicles of different sizes and cellular origin. J Extracell Vesicles9, 1741174 (2020).
64. Choi, D., et al. Mapping Subpopulations of Cancer Cell-Derived Extracellular Vesicles and Particles by Nano-Flow Cytometry. ACS Nano13, 10499-10511 (2019).
65. Crescitelli, R., et al. Subpopulations of extracellular vesicles from human metastatic melanoma tissue identified by quantitative proteomics after optimized isolation. J Extracell Vesicles9, 1722433 (2020).
66. Royo, F., et al. Different EV enrichment methods suitable for clinical settings yield different subpopulations of urinary extracellular vesicles from human samples. J Extracell Vesicles5, 29497 (2016).
67. Lasser, C., Jang, S.C. & Lotvall, J. Subpopulations of extracellular vesicles and their therapeutic potential. Mol Aspects Med60, 1-14 (2018).
68. Thippabhotla, S., Zhong, C. & He, M. 3D cell culture stimulates the secretion of in vivo like extracellular vesicles. Sci Rep9, 13012 (2019).
69. Gudbergsson, J.M., Jonsson, K., Simonsen, J.B. & Johnsen, K.B. Systematic review of targeted extracellular vesicles for drug delivery - Considerations on methodological and biological heterogeneity. J Control Release306, 108-120 (2019).
70. McEvoy, A.C., et al. Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget8, 78890-78900 (2017).